tiprankstipranks
Advertisement
Advertisement

PHVS Stock Latest News

Pharvaris management to meet with Oppenheimer
The FlyPharvaris management to meet with Oppenheimer
5d ago
PHVS
Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
PremiumRatings
Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
7d ago
PHVS
Pharvaris price target raised to $33 from $31 at BofA
PremiumThe Fly
Pharvaris price target raised to $33 from $31 at BofA
20d ago
PHVS
Pharvaris price target lowered to $74 from $75 at Citizens
PremiumThe Fly
Pharvaris price target lowered to $74 from $75 at Citizens
21d ago
PHVS
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
PremiumThe Fly
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
22d ago
PHVS
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
PremiumCompany AnnouncementsPharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
22d ago
6K
PHVS
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
Premium
Company Announcements
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
23d ago
6K
PHVS
Pharvaris price target raised to $31 from $30 at BofA
Premium
The Fly
Pharvaris price target raised to $31 from $30 at BofA
24d ago
PHVS
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
PremiumRatings
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
1M ago
PHVS
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
PremiumThe Fly
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
1M ago
PHVS
Pharvaris price target raised to $52 from $48 at JonesResearch
PremiumThe Fly
Pharvaris price target raised to $52 from $48 at JonesResearch
2M ago
PHVS
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
PremiumRatings
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
2M ago
PHVS
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
PremiumMarket News3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
2M ago
ANET
BCRX
Texas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
Premium
The Fly
Texas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
2M ago
KR
ZS
Pharvaris initiated with an Outperform at Wolfe Research
Premium
The Fly
Pharvaris initiated with an Outperform at Wolfe Research
2M ago
PHVS
Pharvaris price target raised to $42 from $41 at Wedbush
PremiumThe Fly
Pharvaris price target raised to $42 from $41 at Wedbush
2M ago
PHVS
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
PremiumRatings
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
2M ago
PHVS
Pharvaris price target lowered to $51 from $52 at RBC Capital
PremiumThe Fly
Pharvaris price target lowered to $51 from $52 at RBC Capital
2M ago
PHVS
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
PremiumCompany Announcements
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
2M ago
6K
PHVS
Pharvaris reports Q4 EPS (EUR 0.72) vs. (EUR 0.64) last year
PremiumThe FlyPharvaris reports Q4 EPS (EUR 0.72) vs. (EUR 0.64) last year
2M ago
PHVS
Pharvaris announces publications of efficacy, safety evidence on deucrictibant
Premium
The Fly
Pharvaris announces publications of efficacy, safety evidence on deucrictibant
3M ago
PHVS
Pharvaris reports results from study of patient experience during HAE attacks
Premium
The Fly
Pharvaris reports results from study of patient experience during HAE attacks
3M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >